Pulmonary delivery of anti-inflammatory agents

Expert Opinion on Drug Delivery

Volumn 12, Issue 6, 2015, Pages 929-945

  Ali, Mohamed Ehab ^a,b   McConville, Jason T ^c   Lamprecht, Alf ^a,d  

^a UNIVERSITY OF BONN   (Germany)

^b Assiut University   (Egypt)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Anti inflammatory; Inflammation; Inhalation; Lipid nanocarriers; Liposomes; Nanoparticles; Pulmonary delivery

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; BUDESONIDE; CELECOXIB; CORTICOSTEROID; DEXAMETHASONE ACETATE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE; INDOMETACIN; KETOPROFEN; LIPID; LIPOSOME; NANOCARRIER; NANOPARTICLE; OCTANOIC ACID; PIRFENIDONE; POLYMER; PREDNISOLONE; TRIAMCINOLONE ACETONIDE; POWDER;

ASTHMA; BRONCHITIS; BRONCHOSPASM; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RETENTION; DRUG STABILITY; DRUG TARGETING; DRY POWDER; HUMAN; IMMUNOBIOLOGY; IN VIVO STUDY; LIPID VESICLE; LUNG CANCER; LUNG CLEARANCE; LUNG DISEASE; LUNG ENDOTHELIUM; LUNG GRANULOMA; METERED DOSE INHALER; NANOTOXICOLOGY; NEBULIZER; NONHUMAN; PNEUMONIA; REVIEW; SUSPENSION; SUSTAINED DRUG RELEASE; SYSTEMIC THERAPY; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG DISEASES; MEDICINAL CHEMISTRY; METABOLISM; POWDER;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; LUNG; LUNG DISEASES; NANOPARTICLES; POLYMERS; POWDERS;

EID: 84929732509     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.993968     Document Type: Review

References (143)

1. Howard MD, Hood ED, Zern B, et al. Nanocarriers for vascular delivery of antiinflammatory agents. Annu Rev Pharmacol Toxicol 2014;54:205-26
2. Storr J, Lenney CA, Lenney W. Nebulised beclomethasone dipropionate in preschool asthma. Arch Dis Child 1986;61(3):270-3
3. Ferrer MC, Shuvaev VV, Zern BJ, et al. Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One 2014;9(7):e102329
4. Hegeman MA, Cobelens PM, Kamps J, et al. Liposome-encapsulated dexamethasone attenuates ventilatorinduced lung inflammation. Br J Pharmacol 2011;163(5):1048-58
5. Wang W, Zhu R, Xie Q, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012;7:3667-77
6. Brenner JS, Greineder C, Shuvaev V, Muzykantov V. Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin Drug Deliv 2014;1-23
7. Gill S, Lobenberg R, Ku T, et al. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery -A review. J Biomed Nanotechnol 2007;3(2):107-19
8. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002;19(4-5):425-98
9. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19(1):3-36
10. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005;26(35):7260-75
11. Pavord I, Knox A. Pharmacokinetic optimization of inhaled steroid-therapy in asthma. Clin Pharmacokinet 1993;25(2):126-35
12. Freeman CM, Martinez FJ, Han MK, et al. Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. Respir Res 2013;14:13
13. Nadigel J, Prefontaine D, Baglole CJ, et al. Cigarette smoke increases TLR4 and TLR9 expression and induces cytokine production from CD8(+) T cells in chronic obstructive pulmonary disease. Respir Res 2011;12:149
14. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: A regulator of nitric oxide bioavailability. Lab Invest 1996;75(5):617-36
15. Howard MD, Hood ED, Greineder CF, et al. Targeting to endothelial cells augments the protective effect of novel dual bioactive antioxidant/antiinflammatory nanoparticles. Mol Pharm 2014;11(7):2262-70
16. Shuvaev VV, Muzykantov VR. Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release 2011;153(1):56-63
17. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77(4):931-62
18. van Rozendaal BA, van de Lest CH, van Eijk M, et al. Aerosolized endotoxin is immediately bound by pulmonary surfactant protein D in vivo. Biochim Biophys Acta 1999;1454(3):261-9
19. Crapo JD, Harmsen AG, Sherman MP, Musson RA. Pulmonary immunobiology and inflammation in pulmonary diseases. Am J Respir Crit Care Med 2000;162(5):1983-6
20. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998;95(16):9541-6
21. Power JH, Nicholas TE. Immunohistochemical localization and characterization of a rat Clara cell 26-kDa protein (CC26) with similarities to glutathione peroxidase and phospholipase A2. Exp Lung Res 1999;25(5):379-92
22. Wu X, Adedoyin OO, Mansour HM. Pulmonary and nasal anti-inflammatory and anti-Allergy inhalation aerosol delivery systems. Anti Inflamm Anti Allergy Agents Med Chem 2011;10(3):215-29
23. Stockley RA. Role of inflammation in respiratory tract infections. Am J Med 1995;99(6B):8S-13S
24. Huynh PN, Scott LG, Kwong KY. Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol. Ther Clin Risk Manag 2010;6:65-75
25. Zeidler M, Corren J, Tashkin DP. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Curr Med Res Opin 2010;26(6):1295-305
26. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187(4):347-65
27. Barnes PJ. Inhaled corticosteroids in COPD: A controversy. Respiration 2010;80(2):89-95
28. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013;12(7):543-59
29. Physicians desk reference. 48 th edition. Medical Exonomics Data Publication Co; Montrale, NJ: 1994
30. van Grunsven PM, van Schayck CP, Molema J, et al. Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: A meta-Analysis. Thorax 1999;54(4):316-22
31. Aerosol consensus statement. Consensus conference on aerosol delivery. Chest 1991;100(4):1106-9
32. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155(2):542-8
33. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377(9770):1032-45
34. Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104(9):1237-45
35. Stahlhofen W, Gebhart J, Heyder J, et al. Intercomparison of regional deposition of aerosol particles in the human respiratory tract and their longterm elimination. Exp Lung Res 1981;2(2):131-9
36. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-Agonist particle size. Am J Respir Crit Care Med 2005;172(12):1497-504
37. Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996;154(3 Pt 1):771-82
38. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009;124(6 Suppl):S88-93
39. Sakagami M, Kinoshita W, Sakon K, et al. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J Control Release 2002;80(1-3):207-18
40. Vidgren M, Waldrep JC, Arppe J, et al. A Study of Tc-99m-labeled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm 1995;115(2):209-16
41. Gonzalez-Rothi RJ, Suarez S, Hochhaus G, et al. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996;13(11):1699-703
42. Martonen TB, Katz IM. Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm Res 1993;10(6):871-8
43. Wiedmann TS, DeCastro L, Wood RW. Nebulization of NanoCrystals: production of a respirable solid-in-liquidin-Air colloidal dispersion. Pharm Res 1997;14(1):112-16
44. Tang P, Chan HK, Raper JA. Prediction of aerodynamic diameter of particles with rough surfaces. Powder Technol 2004;147(1-3):64-78
45. Crowder TM, Rosati JA, Schroeter JD, et al. Fundamental effects of particle morphology on lung delivery: predictions of Stokes law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002;19(3):239-45
46. Gilani K, Rouholamini Najafabadi A, Barghi M, Rafiee-Tehrani M. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers. Eur J Pharm Biopharm 2004;58(3):595-606
47. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1998;1(9):394-8
48. Feeley JC, York P, Sumby BS, Dicks H. Determination of surface properties and how characteristics of salbutamol sulphate, before and after micronisation. Int J Pharm 1998;172(1-2):89-96
49. Muller R, Peters K, Becker R, Kruss B. Nanosuspensions for the i.v. administration of poorly soluble drugs -stability during sterilization and longterm storage. Proceed Intern Symp Control Rel Bioact Mater 1996;22:574-5
50. Waltersson J, Lundgren P. The effect of mechanicalcomminution on drug stability. Acta Pharm Suec 1985;22(5):291-300
51. Vidgren MT, Vidgren PA, Paronen TP. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium-cromoglycate. Int J Pharm 1987;35(1-2):139-44
52. Steckel H, Thies J, Muller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm 1997;152(1):99-110
53. Steckel H, Muller BW. Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. Int J Pharm 1998;173(1-2):25-33
54. Bakhbakhi Y, Charpentier PA, Rohani S. Experimental study of the GAS process for producing microparticles of beclomethasone-17, 21-dipropionate suitable for pulmonary delivery. Int J Pharm 2006;309(1-2):71-80
55. Rasenack N, Steckel H, Muller BW. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci 2003;92(1):35-44
56. Steckel H, Rasenack N, Villax P, Muller BW. In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. Int J Pharm 2003;258(1-2):65-75
57. Steckel H, Rasenack N, Muller BW. In-situ-micronization of disodium cromoglycate for pulmonary delivery. Eur J Pharm Biopharm 2003;55(2):173-80
58. Murnane D, Martin GP, Marriott C. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals. J Pharm Sci 2009;98(2):503-15
59. Ostrander KD, Bosch HW, Bondanza DM. An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999;48(3):207-15
60. Ali R, Mittal G, Kumar M, et al. Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases. J Microencapsul 2013;30(6):546-58
61. Brogden RN, Pinder RM, Sawyer PR, et al. Beclomethasone dipropionate inhaler: A review of its pharmacology, therapeutic value and adverse effects. I: Asthma. Drugs 1975;10(3):166-210
62. Brogden RN, Heel RC, Speight TM, Avery GS. Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984;28(2):99-126
63. El-Baseir MM, Phipps MA, Kellaway IW. Preparation and subsequent degradation of polyL-lactic acid microspheres suitable for aerosolisation: A physico-chemical study. Int J Pharm 1997;151:145-53
64. Limayem I, Charcosset C, Fessi H. Purification of nanoparticle suspensions by a concentration/diafiltration process. Sep Purif Technol 2004;38(1):1-9
65. Bandi N, Ayalasomayajula SP, Dhanda DS, et al. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 2005;57(7):851-60
66. Trivedi R, Redente EF, Thakur A, et al. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012;23(50):505101
67. Yoo D, Guk K, Kim H, et al. Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int J Pharm 2013;450(1-2):87-94
68. Kim S, Park H, Song Y, et al. Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials 2011;32(11):3021-9
69. Lim EJ, Kang HJ, Jung HJ, Park EH. Anti-Angiogenic, anti-inflammatory and anti-nociceptive activity of 4-hydroxybenzyl alcohol. J Pharm Pharmacol 2007;59(9):1235-40
70. Kim HJ, Hwang IK, Won MH. Vanillin, 4-hydroxybenzyl aldehyde and 4-hydroxybenzyl alcohol prevent hippocampal CA1 cell death following global ischemia. Brain Res 2007;1181:130-41
71. Gaber NN, Darwis Y, Peh KK, Tan YT. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. J Nanosci Nanotechnol 2006;6(9-10):3095-101
72. Arya V, Coowanitwong I, Brugos B, et al. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. J Drug Target 2006;14(10):680-6
73. Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013;34(13):3439-46
74. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009;26(1):244-9
75. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9(8):615-27
76. Waldrep JC, Scherer PW, Hess GD, et al. Nebulized glucocorticoids in liposomes -Aerosol characteristics and human dose estimates. J Aerosol Med 1994;7(2):135-45
77. Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994;105(1):106-10
78. Gonzalezrothi RJ, Schreier H. Pulmonary delivery of liposome-encapsulated drugs in asthma therapy. Clin Immunother 1995;4(5):331-7
79. Mihalko PJ, Schreier H, Abra RM. Liposomes: A pulmonary perspective. In: Gregoriadis G, editor. Liposomes as drug carriers. Wiley; Chichester, UK: 1988. p. 679-94
80. Saari SM, Vidgren MT, Koskinen MO, et al. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998;113(6):1573-9
81. Saari M, Vidgren MT, Koskinen MO, et al. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 1999;181(1):1-9
82. Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 1997;111(2):316-23
83. Elhissi AMA, Islam MA, Arafat B, et al. Development and characterisation of freeze-dried liposomes containing two anti-Asthma drugs. Micro Nano Lett 2010;5(3):184-8
84. Farr SJ, Kellaway IW, Carmanmeakin B. Comparison of solute partitioning and efflux in liposomes formed by a conventional and an aerosolized method. Int J Pharm 1989;51(1):39-46
85. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipidcomposition. Pharm Res 1990;7(11):1127-33
86. Schreier H, Gonzalezrothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J Control Release 1993;24(1-3):209-23
87. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res 1991;8(2):217-21
88. Niven RW, Carvajal TM, Schreier H. Nebulization of Liposomes. 3. The effects of operating-conditions and local environment. Pharm Res 1992;9(4):515-20
89. Schreier H, Lukyanov AN, Hochhaus G, Gonzalez-Rothi RJ. Thermodynamic and kinetic aspects of the interaction of triamcinolone acetonide with liposomes. Proc Int Symp Cont Rel Bioact Mater 1994;21:228-9
90. Taylor KMG, Taylor G, Kellaway IW, Stevens J. The stability of liposomes to nebulization. Int J Pharm 1990;58(1):57-61
91. Hochhaus G, Gonzalez-Rothi RJ, Lukyanov A, et al. Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. Pharm Res 1995;12(1):134-7
92. Suarez S, Gonzalez-Rothi RJ, Schreier H, Hochhaus G. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1998;15(3):461-5
93. Konduri KS, Nandedkar S, Duzgunes N, et al. Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 2003;111(2):321-7
94. Konduri KS, Nandedkar S, Rickaby DA, et al. The use of sterically stabilized liposomes to treat asthma. Methods Enzymol 2005;391:413
95. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85(18):6949-53
96. Grit M, Desmidt JH, Struijke A, Crommelin DJA. Hydrolysis of phosphatidylcholine in aqueous liposome dispersions. Int J Pharm 1989;50(1):1-6
97. Hunt CA, Tsang S. Alpha-tocopherol retards autoxidation and prolongs the shelf-life of liposomes. Int J Pharm 1981;8(2):101-10
98. Schreier H, Mobley WC, Concessio N, et al. Formulation and in-vitro performance of liposome powder aerosols. Stp Pharma Sci 1994;4(1):38-44
99. Darwis Y, Kellaway IW. Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes. Int J Pharm 2001;215(1-2):113-21
100. Mehnert W, Mader K. Solid lipid nanoparticles -production, characterization and applications. Adv Drug Deliv Rev 2001;47(2-3):165-96
101. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242(1-2):121-8
102. Pardeike J, Weber S, Haber T, et al. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011;419(1-2):329-38
103. Hu L, Jia Y, WenDing Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie 2010;65(8):585-7
104. Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356(1-2):333-44
105. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85(4):227-34
106. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J Nanosci Nanotechnol 2011;11(3):1841-51
107. Patlolla RR, Chougule M, Patel AR, et al. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010;144(2):233-41
108. Chattopadhyay P, Shekunov BY, Yim D, et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007;59(6):444-53
109. Zhang P-R, Tu Y-F, Wang S, et al. Preparation and characterization of budesonide-loaded solid lipid nanoparticles for pulmonary delivery. J Chin Pharm Sci 2011;20:390-6
110. Weber S, Bauer B, Zimmer A, Pardeike J. Dexamethasone-loaded NLC: A stable carrier system for pulmonary application by jet stream nebulization. 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; Istanbul; 2012
111. Terzano C, Allegra L, Alhaique F, et al. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm 2005;59(1):57-62
112. Muro S, Muzykantov VR. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005;11(18):2383-401
113. Muro S, Wiewrodt R, Thomas A, et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003;116(Pt 8):1599-609
114. Wiewrodt R, Thomas AP, Cipelletti L, et al. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 2002;99(3):912-22
115. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003;285(2):L283-92
116. Danilov SM, Muzykantov VR, Martynov AV, et al. Lung is the target organ for a monoclonal antibody to angiotensin-converting enzyme. Lab Invest 1991;64(1):118-24
117. Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release 2014;177:34-41
118. Anselmo AC, Gupta V, Zern BJ, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 2013;7(12):11129-37
119. Ding BS, Hong N, Christofidou-Solomidou M, et al. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Resp Crit Care Med 2009;180(3):247-56
120. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008;60(8):863-75
121. Dailey LA, Jekel N, Fink L, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006;215(1):100-8
122. Roberts RA, Shen T, Allen IC, et al. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano-And microscale particles. PLoS One 2013;8(4):e62115
123. Stuart D, Lobenberg R, Ku T, et al. Biophysical investigation of nanoparticle interactions with lung surfactant model systems. J Biomed Nanotechnol 2006;2(3-4):245-52
124. Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997;37(10):881-92
125. Mollmann H, Derendorf H, Barth J, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 1997;37(10):893-903
126. Passali D, Lauriello M, Mezzedimi C, Bellussi L. Nasal allergy and atmospheric pollution. Int J Pediatr Otorhinolaryngol 1999;49(Suppl 1):S257-60
127. Schlesinger RB, Chen LC, Driscoll KE. Exposure-response relationship of bronchial mucociliary clearance in rabbits following acute inhalations of sulfuric acid mist. Toxicol Lett 1984;22(2):249-54
128. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1(3):297-315
129. Ensign LM, Schneider C, Suk JS, et al. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater 2012;24(28):3887-94
130. White CW, Jackson JH, Abuchowski A, et al. Polyethylene glycol-Attached antioxidant enzymes decrease pulmonary oxygen-toxicity in rats. J Appl Physiol 1989;66(2):584-90
131. Shuvaev VV, Han JY, Yu KJ, et al. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J 2011;25(1):348-57
132. Taylor KMG, Hoare C. Ultrasonic nebulization of pentamidine isethionate. Int J Pharm 1993;98(1-3):45-9
133. Bridges PA, Taylor KMG. Nebulisers for the generation of liposomal aerosols. Int J Pharm 1998;173(1-2):117-25
134. Dennis JH, Stenton SC, Beach JR, et al. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax 1990;45(10):728-32
135. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J Liposome Res 2006;16(2):113-25
136. Elhissi A, Hidayat K, Phoenix DA, et al. Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm 2013;444(1-2):193-9
137. Tewa-Tagne P, Briancon S, Fessi H. Spray-dried microparticles containing polymeric nanocapsules: formulation aspects, liquid phase interactions and particles characteristics. Int J Pharm 2006;325(1-2):63-74
138. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002;99(19):12001-5
139. Lebhardt T, Roesler S, Uusitalo HP, Kissel T. Surfactant-free redispersible nanoparticles in fast-dissolvingcomposite microcarriers for dry-powder inhalation. Eur J Pharm Biopharm 2011;78(1):90-6
140. Yamamoto H, Kurashima H, Katagiri D, et al. Poly(lactic-co-glycolic acid) nanospherecomposite prepared with Mechanofusion dry powdercomposition system for improving pulmonary insulin delivery with dry powder inhalation. J Pharm Sci Technol Jpn 2004;64:245-53
141. Yamamoto H, Hoshina W, Kurashima H, et al. Engineering of poly (DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Adv Powder Technol 2007;18(2):215-28
142. Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm 2014;87(3):510-17
143. Cheow WS, Ng ML, Kho K, Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freezedrying adjuvants. Int J Pharm 2011;404(1-2):289-300